Home » Authors » James Etheridge

Articles by James Etheridge

Neurotech Acquires Exclusive License From Amgen For CNTF

Jan. 16, 2002

By James Etheridge

Neurotech Acquires Exclusive License From Amgen For CNTF

Jan. 16, 2002

By James Etheridge

French Parliament Could Vote To Allow Therapeutic Cloning

Jan. 16, 2002

By James Etheridge

ExonHit Partners With IDEC To Develop Antibody Therapeutics

Jan. 9, 2002

By James Etheridge

PARIS - ExonHit Therapeutics SA and IDEC Pharmaceuticals Corp. signed a collaboration and research agreement aimed at discovering new antigen targets for antibody therapy, with a particular focus on prostate carcinoma.

ExonHit Partners With IDEC To Develop Antibody Therapeutics

Jan. 9, 2002

By James Etheridge

PARIS - ExonHit Therapeutics SA and IDEC Pharmaceuticals Corp. signed a collaboration and research agreement aimed at discovering new antigen targets for antibody therapy, with a particular focus on prostate carcinoma.

Crucell Unveils AdVac, Its New Genetic Vaccination Technology

June 6, 2001

By James Etheridge

Crucell Unveils AdVac, Its New Genetic Vaccination Technology

June 6, 2001

By James Etheridge

Transgene Financing Nets $54M; BioMérieux Stake Reaches 70%

May 30, 2001

By James Etheridge

Hybrigenics, Institut Curie Create Joint Cancer Research Facility

May 30, 2001

By James Etheridge

Neurotech Raises $30M Privately To Fund Work In Cell Therapies

May 30, 2001

By James Etheridge

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 11, 2024.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for December 11, 2024.
Boryung invests $10M in Intuitive Machines for outer space R&D
BioWorld
Following its $60 million investment in Axiom Space Inc. last year, Boryung Co. Ltd. made a $10 million private placement in Intuitive Machines Inc. to grow its...
Phase II Huntington’s tie-up with Novartis could edge $3B for PTC
BioWorld
PTC Therapeutics Inc. said a “highly competitive process with several parties involved” led to the deal centered on the firm’s Huntington’s disease program with...
Elevar nabs Relay’s FGFR2 rare cancer drug in $500M deal
BioWorld
Elevar Therapeutics Inc. will license Relay Therapeutics Inc.’s “NDA-ready” bile duct cancer therapy, lirafugratinib (RLY-4008), through a potential $500 million...

BioWorld Premium

Enjoy extended coverage for the most complete market view with BioWorld, BioWorld MedTech, and BioWorld Asia in a single, easy to access subscription.